Serotonin transporters in dopamine transporter imaging: A head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I

Journal of Nuclear Medicine

Volumn 51, Issue 12, 2010, Pages 1885-1891

  Ziebell, Morten ^a   Holm Hansen, Signe ^a   Thomsen, Gerda ^a   Wagner, Aase ^a   Jensen, Peter ^a   Pinborg, Lars H ^a   Knudsen, Gitte Moos ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

123I FP CIT (DaTSCAN); 123I PE2I; SPECT

Indexed keywords

2 BETA CARBOMETHOXY 3BETA (4 IODOPHENYL) N (3 FLUOROPROPYL)NORTROPANE I 123; CITALOPRAM; DOPAMINE TRANSPORTER; N (3 IODOPROPENYL) 2 BETA CARBOMETHOXY 3BETA (4 METHYLPHENYL) I 123; RADIOLIGAND; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BOLUS INJECTION; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS;

ADULT; AGED; BINDING, COMPETITIVE; BRAIN; CITALOPRAM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOSTRIATUM; NORTROPANES; PROTEIN BINDING; RADIOPHARMACEUTICALS; SCINTILLATION COUNTING; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES; YOUNG ADULT;

EID: 78651345177     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.078337     Document Type: Article

References (27)

1. Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse. 1989;4:371-377.
2. 123I]-2 β-carbomethoxy-3 β-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem. 1991;34:3144-3146.
3. Neumeyer JL, Wang S, Gao Y, et al. N-ω-fluoroalkyl analogs of (1R)-2 β-carbomethoxy-3 β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem. 1994;37:1558-1561.
4. 123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med. 1998;25:24-30.
5. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J Nucl Med. 1996;37:1129-1133.
6. 18F] cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;13:24-42.
7. 123I]FP- CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35:424-438.
8. Emond P, Garreau L, Chalon S, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2β-carbomethoxy-3β-(4′- iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2β-carbomethoxy-3β- (3′,4′-disubstituted phenyl)nortropane - new high-affinity and selective compounds for the dopamine transporter. J Med Chem. 1997;40:1366-1372.
9. Kuikka JT, Baulieu JL, Hiltunen J, et al. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging. Eur J Nucl Med. 1998;25:531-534.
10. 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. J Nucl Med. 2005;46:1119-1127.
11. 123I]PE2I binding to dopamine transporters with SPECT. Eur J Nucl Med Mol Imaging. 2007;34:101-109.
12. 11C]PE2I and positron emission tomography. J Cereb Blood Flow Metab. 2009;29:1332-1345.
13. Seibyl JP, Marek K, Sheff K, et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med. 1998;39:1500-1508.
14. 123I]PE2I metabolism [abstract]. Eur J Nucl Med. 1999;26:1139.
15. Ziebell M, Pinborg LH, Thomsen G, et al. MRI-guided region-of-interest delineation is comparable to manual delineation in dopamine transporter SPECT quantification in patients: a reproducibility study. J Nucl Med Technol. 2010;38:61-68.
16. Kretschmann H-J, Weinrich W. Neuroanatomy and Cranial Computed Tomography. Stuttgart, Germany: Thieme; 1986.
17. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539.
18. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
19. 125I]PE2I. Neuroimage. 1999;9:108-116.
20. Madras BK, Gracz LM, Fahey MA, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Synapse. 1998;29:116-127.
21. Varnas K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp. 2004;22:246-260.
22. 11C]DASB PET study. Neuroimage. 2009;49:121-126.
23. 11C-DASB in healthy humans: reproducibility and comparison of methods. J Nucl Med. 2006;47:815-826.
24. Booij J, Habraken JB, Bergmans P, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998;39:1879-1884.
25. 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007;48:359-366.
26. 123I]β-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin re-uptake inhibitor citalopram. Neuropsychopharmacology. 2005;30:996-1005.
27. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003;28:413-420.